Ethical and Regulatory Perspectives on Compassionate Use in Rare Disease Treatment

Understanding Compassionate Use and Expanded Access Programs

For patients with rare and life-threatening diseases, conventional treatment options are often limited or nonexistent. When clinical trial participation is not feasible due to geographic, medical, or eligibility limitations, compassionate use—or expanded access—offers a critical alternative pathway for accessing investigational therapies outside of clinical trials. These programs allow patients to receive potentially life-saving treatments before formal regulatory approval, under strict conditions and ethical oversight.

Expanded Access Programs (EAPs) are regulated by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offering a structured mechanism for pre-approval treatment in exceptional circumstances. In rare disease communities, where the urgency of need is amplified by the lack of alternatives, EAPs are often the only hope for patients with deteriorating conditions.

Regulatory Frameworks Across Different Jurisdictions

The regulatory approach to compassionate use varies by region. Understanding these frameworks is crucial for sponsors and clinicians working in rare disease spaces.

• FDA (USA): Allows expanded access under 21 CFR 312 Subpart I. Individual, intermediate-size, and widespread EAPs are permitted. IRB approval and informed consent are required.
• EMA (EU): Each member state regulates access, though guidance exists under Article 83 of Regulation (EC) No 726/2004. Sponsors typically coordinate with national agencies like ANSM (France) or MHRA (UK).
• Japan: Provides an Early Access Program (EAP) to allow use of unapproved drugs after positive Phase II data.
• Australia: Offers the Special Access Scheme (SAS) through the Therapeutic Goods Administration (TGA).

For example, a biotech company providing a gene therapy for a rare metabolic disorder implemented a multi-country EAP following positive Phase II results, using local regulations to support early access in Canada, Brazil, and Italy.

Ethical Principles Underpinning Compassionate Use

Despite its noble intent, expanded access raises important ethical considerations, particularly regarding fairness, safety, and resource allocation. Core principles include:

• Equity: Access should not be limited to those with greater resources or advocacy.
• Transparency: Criteria for eligibility and prioritization must be clearly defined.
• Non-maleficence: Risks must be weighed against uncertain benefits.
• Informed consent: Patients must fully understand the experimental nature of the treatment.
• Scientific integrity: Access should not compromise ongoing clinical trials.

For instance, in one EAP for a rare pediatric neurodegenerative condition, the sponsor worked with bioethicists and advocacy groups to design an allocation process that included medical urgency, age limits, and geographic representation as key criteria.

Process for Implementing an Expanded Access Program

Setting up an EAP requires alignment between sponsors, investigators, regulators, and ethics committees. Typical steps include:

1. Determine eligibility: Only patients with serious or life-threatening conditions and no alternative treatment options qualify.
2. Submit documentation: An IND or protocol amendment must be submitted to FDA or relevant local authority.
3. Obtain IRB approval: Even for single-patient access, institutional oversight is necessary.
4. Informed consent: Must outline risks, benefits, and the unapproved status of the drug.
5. Drug supply coordination: Sponsors must ensure proper labeling, storage, and monitoring of the investigational product.
6. Adverse event reporting: Safety data must be collected and reported.

Expanded access is not a “back door” to treatment—it’s a carefully regulated bridge between clinical trials and formal market approval.

Challenges in Compassionate Use Implementation

Despite growing demand, EAPs are logistically and ethically complex. Common challenges include:

• Manufacturing capacity: Sponsors may have limited supplies of the investigational drug.
• Cost recovery: Many jurisdictions prohibit charging patients, posing financial strain on developers.
• Regulatory complexity: Each country has different timelines, documentation, and legal requirements.
• Patient selection: Ethical dilemmas arise when more patients seek access than the program can support.

In a real-world case, a biotech firm offering a rare enzyme replacement therapy faced overwhelming demand. A third-party ethics board was established to manage patient prioritization and ensure fair distribution based on clinical need.

The Role of Advocacy and Patient Engagement

Patient advocacy organizations play a crucial role in facilitating expanded access by:

• Educating families about compassionate use rights and options
• Connecting patients to enrolling EAPs or relevant sponsors
• Lobbying regulators for expedited access in ultra-rare indications
• Helping sponsors understand patient priorities and burdens

For example, advocacy groups like NORD and EURORDIS regularly partner with sponsors to build ethical frameworks for expanded access in ultra-rare diseases, ensuring programs are patient-centered and community-informed.

Right-to-Try Laws: Parallel or Problematic?

Some countries, like the U.S., have implemented “Right-to-Try” legislation allowing patients to directly request investigational drugs without FDA oversight. While this may sound empowering, ethical concerns remain:

• Bypasses standard safety reviews and IRB protections
• Lacks structured adverse event reporting
• Places pressure on sponsors to approve access requests without clear criteria

Many ethicists advocate for structured expanded access over Right-to-Try due to its stronger safeguards and data integrity. Still, both frameworks reflect the growing demand for earlier patient access to promising treatments.

Conclusion: Balancing Compassion and Caution

Compassionate use and expanded access are powerful tools for addressing the unmet needs of rare disease patients. When thoughtfully designed and ethically implemented, these programs offer hope to those who might otherwise face devastating outcomes. Yet they also demand careful balancing of urgency, fairness, and scientific rigor.

Sponsors and clinicians must collaborate with regulators, advocacy groups, and patient families to ensure that these programs remain ethically grounded, transparently administered, and focused on maximizing benefit while minimizing harm. As rare disease therapies continue to evolve, compassionate access will remain a critical complement to traditional clinical trial pathways.

Navigating Ethics in Pediatric Rare Disease Clinical Trials

Why Pediatric Rare Disease Trials Require Special Ethical Attention

Conducting clinical trials in pediatric populations with rare diseases presents a unique set of ethical, regulatory, and operational challenges. These children often suffer from severe, progressive, or life-threatening conditions with limited or no existing treatment options, which amplifies the urgency for clinical research. However, children are considered a vulnerable population under regulatory frameworks such as ICH E6(R2), FDA 21 CFR 50 Subpart D, and the EU Clinical Trials Regulation.

Balancing the need to advance therapy development with the obligation to protect young participants is a nuanced ethical undertaking. Pediatric trials must address questions of informed consent and assent, risk minimization, equitable enrollment, long-term follow-up, and the psychological and physical impact of trial participation on children and their families.

Informed Consent and Pediatric Assent: A Dual Responsibility

While legal guardians provide consent for children to participate in clinical trials, ethical guidelines also stress the importance of seeking assent from the child when developmentally appropriate. Assent is more than a formality—it’s a process of engaging the child in the decision to participate, tailored to their cognitive and emotional maturity.

Best practices include:

• Using age-appropriate language and visuals in assent forms
• Involving child psychologists or trained staff to explain procedures
• Respecting dissent—even when legal consent is given by parents

For example, a study on a rare neuromuscular disorder used illustrated assent documents and interactive video tools to help children aged 7–11 understand the concept of randomization and blood draws. Feedback from both children and caregivers led to higher engagement and lower dropout rates.

Risk-Benefit Assessment in Pediatric Rare Disease Trials

Regulators require that pediatric trials involving greater than minimal risk must present the prospect of direct benefit to the child. In rare disease trials, this line is often difficult to define due to the lack of prior safety data and the urgent nature of the diseases. Therefore, ethics committees and sponsors must carefully justify:

• The scientific rationale for involving children in early-phase trials
• The likelihood and magnitude of potential benefit
• Alternatives to participation (e.g., expanded access programs)

For instance, a Phase I gene therapy trial for a rare pediatric blindness disorder was approved based on preclinical evidence and natural history data demonstrating rapid degeneration in untreated patients, making early intervention ethically justifiable despite unknown long-term risks.

Family-Centered Trial Design and Burden Minimization

Families of children with rare diseases often experience high levels of emotional, financial, and logistical stress. Ethical trial design must consider these burdens and offer practical accommodations, such as:

• Flexible scheduling to avoid school disruption
• Home visits or telemedicine options
• Travel and lodging support
• Access to genetic counseling or psychosocial support

In one multinational rare epilepsy study, researchers provided a mobile nursing service and interpreter support for non-English-speaking families. This not only increased trial enrollment among underrepresented populations but also enhanced compliance and satisfaction.

Equitable Enrollment and Avoiding Therapeutic Misconception

In rare disease contexts, desperation for a cure can blur the line between clinical care and research. This is particularly true for parents, who may view participation as their only hope. Sponsors and investigators must take care to:

• Clearly differentiate research from therapy in consent discussions
• Reiterate that trial participation is voluntary and may not offer personal benefit
• Avoid coercive language or excessive optimism

Ethics committees often require that consent documents include language emphasizing the experimental nature of the intervention and the possibility of receiving a placebo. Transparency builds trust and upholds the dignity of participants.

Global Regulatory Considerations and Pediatric Ethics

Pediatric rare disease trials frequently span multiple countries. This raises challenges related to differing legal age of consent, ethics board requirements, and interpretation of “minimal risk.” Investigators must ensure that local regulations align with international ethical standards. Tools like ISRCTN help researchers align protocols with jurisdiction-specific consent rules.

For example:

• In the EU, pediatric trials require a Pediatric Investigation Plan (PIP) approved by the EMA
• In the U.S., IRBs must evaluate additional safeguards under Subpart D of 21 CFR 50
• In Japan, consent procedures may involve both parents unless specific exceptions apply

Ethical harmonization across countries is crucial for maintaining study integrity and avoiding regulatory delays.

Placebo Use and Compassionate Access in Pediatric Trials

Using placebos in pediatric rare disease studies is ethically sensitive. Placebos are generally discouraged when standard care is available. When necessary, sponsors should consider strategies such as:

• Short placebo exposure with early escape criteria
• Add-on designs that compare investigational drugs with existing therapies
• Open-label extensions for all participants post-trial

In severe degenerative diseases, compassionate use or expanded access programs should be considered for patients not meeting eligibility or for those who deteriorate during screening. These programs must be designed with regulatory oversight and transparent criteria.

Data Protection and Long-Term Follow-Up Ethics

Pediatric trials often require long-term follow-up, particularly for gene therapy, immunomodulatory, or metabolic interventions. This introduces ethical considerations around data use, re-consent upon reaching the age of majority, and long-term data privacy.

Best practices include:

• Informing families at enrollment about long-term data use plans
• Planning for re-consent at age 18 (or local legal age)
• Ensuring secure storage of genetic and clinical data for years

Trials registered in ClinicalTrials.gov and similar platforms often include detailed statements on follow-up procedures and data retention policies to comply with ethics board and GDPR expectations.

Conclusion: Advancing Pediatric Trials with Compassionate Ethics

Ethical excellence in pediatric rare disease trials is not just about regulatory compliance—it’s about safeguarding dignity, autonomy, and hope. By prioritizing transparent communication, reducing burden, and upholding rigorous ethical standards, researchers can create a framework of trust and care for families navigating the uncertainty of rare conditions.

Through patient-centered design, stakeholder engagement, and international harmonization, pediatric trials can be both scientifically robust and ethically sound—ultimately accelerating therapeutic innovation for those who need it most.

Protecting Patient Privacy in Rare Disease Recruitment Campaigns

Why Privacy Matters in Rare Disease Recruitment

Rare disease clinical trials often target small, identifiable populations. This amplifies privacy risks during recruitment. Sharing health data—whether through registries, digital campaigns, or social media—must be handled with utmost care. Failure to respect privacy not only undermines trust but also risks violating global data protection regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA).

In the digital age, recruitment campaigns leverage online platforms, patient communities, mobile apps, and AI-based tools to find eligible participants. While effective, these strategies increase exposure of personally identifiable information (PII) and protected health information (PHI), which, if mishandled, can lead to serious legal and ethical consequences.

Understanding the Regulatory Landscape: GDPR and HIPAA

Clinical trial sponsors operating in multiple jurisdictions must navigate complex data privacy laws:

• GDPR (EU): Requires explicit consent, data minimization, purpose limitation, and rights to access and erasure. Violations can result in fines up to €20 million or 4% of global turnover.
• HIPAA (US): Regulates PHI by covered entities. Requires safeguards, breach notification, and minimum necessary use. Applies to recruitment if data is sourced from healthcare providers or payers.

Other regions (e.g., Brazil’s LGPD, Canada’s PIPEDA, and India’s DPDP Act) are also adopting stringent privacy laws, making global compliance a non-negotiable part of trial planning.

Consent and Transparency: The Cornerstones of Ethical Recruitment

Patient recruitment begins with consent. This means clear, accessible communication about:

• What data is being collected (e.g., genetic, medical history, contact info)
• How it will be used (e.g., pre-screening, outreach, registry inclusion)
• Who will access it (e.g., sponsors, CROs, third-party platforms)
• How long it will be stored and whether it will be anonymized

Best practice includes layered consent forms, where patients can choose which data to share, and how. IRBs must review all consent mechanisms, especially when recruitment uses cookies, social media, or third-party data brokers.

Risks of Re-Identification in Rare Disease Communities

Due to small cohort sizes and distinctive genetic profiles, rare disease data is inherently more re-identifiable. Even after removing names or emails, combining datasets (e.g., birth year, zip code, and diagnosis) can reveal identities. This risk is especially high in ultra-rare disorders with fewer than 100 known cases globally.

Case example: In one rare metabolic disorder trial, participants were inadvertently identified when a sponsor shared anonymized site-level data with investigators, who cross-referenced it with registry details. This led to public concern and IRB-imposed corrective actions.

Privacy by Design: Building Safeguards into Recruitment Tools

Recruitment platforms and digital tools must be designed with privacy in mind from the start. Key principles include:

• Data Minimization: Collect only what’s essential for screening and eligibility.
• Encryption: Use HTTPS and AES-256 standards for data at rest and in transit.
• Access Control: Role-based permissions limit who sees which patient information.
• Audit Trails: Maintain logs of who accessed, edited, or exported data.

Platforms should also provide participants with user-friendly dashboards to view, edit, or withdraw their data at any time.

Role of Third-Party Vendors and Data Sharing Agreements

Digital recruitment often involves external vendors—advertising platforms, data analytics firms, registry partners, and app developers. Each third party must sign a Data Processing Agreement (DPA) outlining:

• What data they handle
• How it’s protected
• What happens in the event of a breach

Sponsors are ultimately responsible for breaches caused by their vendors, making due diligence and vendor qualification essential. All agreements must align with regional privacy laws and be approved by legal and compliance teams.

Communicating Privacy Protections to Participants

Recruitment success relies on trust. Sponsors should openly communicate their privacy practices in all outreach materials. Recommended inclusions:

• Simple privacy policies linked in digital ads and pre-screening tools
• FAQs about data use during the trial and afterward
• Dedicated contact points for privacy questions or complaints

One successful example is a Canadian rare disease study that hosted monthly webinars explaining data handling and participant rights. This transparency increased recruitment rates by 30%.

Monitoring Compliance and Responding to Breaches

Sponsors should implement monitoring programs to detect and respond to data privacy incidents:

• Conduct internal audits of recruitment platforms
• Maintain incident response plans, including breach notification timelines
• Regularly train staff on privacy protocols and patient data sensitivity

All breaches—even minor ones—must be logged and investigated. Major breaches must be reported to regulatory authorities within stipulated timeframes (e.g., 72 hours under GDPR).

Conclusion: Protecting Privacy Is Fundamental to Rare Disease Research

In a space where patients are already vulnerable—medically, emotionally, and socially—ensuring data privacy is not just a regulatory checkbox; it’s a moral imperative. Ethical recruitment practices, secure platforms, and informed transparency build the trust needed to sustain long-term participation in rare disease trials.

As rare disease research increasingly leverages digital technologies and global collaborations, sponsors must stay vigilant, adaptive, and patient-centric in their approach to privacy. Doing so not only safeguards participants—but also strengthens the integrity and success of every clinical trial.

Creating High-Impact Rare Disease Registries to Support Clinical Research

The Strategic Value of Patient Registries in Rare Disease Trials

For rare diseases, traditional recruitment methods often fall short due to small, dispersed patient populations and diagnostic delays. Patient registries help bridge this gap by offering centralized databases of diagnosed or at-risk individuals, enabling sponsors and investigators to identify, screen, and engage patients more efficiently.

Registries are invaluable for tracking disease progression, defining natural history, identifying potential biomarkers, and supporting real-world evidence generation. In addition, regulators like the FDA and EMA increasingly encourage the use of registry data to inform study design and accelerate orphan drug development programs.

For example, the use of a rare neuromuscular disease registry allowed sponsors to predict baseline functional scores more accurately, improving the statistical power of a pivotal trial while using fewer patients.

Key Elements of an Effective Rare Disease Registry

A successful patient registry must be built with robust architecture, clear governance, and compliance with regional data protection laws. The following components are critical:

• Standardized Data Collection: Use globally accepted terminology (e.g., MedDRA, SNOMED CT) and case report forms tailored for the disease.
• Longitudinal Tracking: Registries should allow long-term follow-up, capturing disease progression, therapy changes, and patient-reported outcomes (PROs).
• Interoperability: Integration with Electronic Health Records (EHR), Clinical Trial Management Systems (CTMS), and Electronic Data Capture (EDC) platforms is crucial.
• Privacy and Compliance: Ensure HIPAA (US), GDPR (EU), and local regulations are addressed, including de-identification, consent, and data storage policies.
• Governance and Access Controls: A governing board must manage registry access and monitor data use to prevent misuse and ensure scientific integrity.

Steps to Build a Rare Disease Patient Registry

The process of establishing a registry includes planning, stakeholder engagement, technical development, and launch. A typical roadmap includes:

1. Needs Assessment: Define objectives—recruitment, natural history study, RWE, or trial optimization.
2. Protocol Development: Draft registry protocol, including inclusion/exclusion criteria, data fields, visit schedules, and e-consent mechanisms.
3. IRB and Regulatory Approval: Submit for Institutional Review Board and data protection authority review.
4. Platform Selection: Use REDCap, OpenClinica, or commercial systems with customizable modules and multilingual support.
5. Stakeholder Engagement: Collaborate with advocacy groups, clinicians, and patient networks for enrollment and retention.
6. Pilot Testing: Conduct a soft launch to evaluate usability and identify data quality issues.
7. Launch and Monitoring: Go live, monitor enrollment metrics, and conduct periodic data audits.

Case Study: European Rare Disease Registry Network (ERDRI)

The European Rare Disease Registry Infrastructure (ERDRI), coordinated by the European Joint Programme on Rare Diseases (EJP RD), is a cross-border platform that connects multiple national and disease-specific registries. It has standardized metadata and unique patient identifiers to enable data pooling across the EU, facilitating better research collaboration and clinical trial readiness.

By providing tools such as the Common Data Elements (CDE) and the ERDRI.dor (directory of registries), it supports interoperability, reduces duplication, and helps locate eligible participants across borders. This model is especially useful in trials requiring pan-European recruitment.

Integrating Registries into Clinical Trial Recruitment

Registries play a direct role in identifying and contacting eligible patients for clinical trials. With appropriate patient consent, registry administrators can notify participants about trial opportunities and pre-screen for eligibility. This significantly shortens recruitment timelines.

Many registries also integrate algorithms that use genetic markers, clinical profiles, and geographic proximity to match patients with upcoming studies. For instance, a US-based rare metabolic disease registry reduced trial enrollment time by 40% by leveraging predictive modeling and geo-targeted notifications.

Regulatory Expectations and Data Quality Assurance

Regulatory agencies require that registry data used for trial planning or submission meet high standards of accuracy, completeness, and traceability. This includes audit trails, version control, and adherence to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate).

To ensure this, registry sponsors should implement continuous data monitoring plans, employ built-in edit checks, and conduct periodic data verification activities. Documentation of these controls is essential, especially if registry data is to be used in submissions or as external control arms.

Leveraging Global Resources and Registries

While building disease-specific registries is ideal, clinical trial sponsors can also tap into global or national registries already in operation. These may include government-funded initiatives, nonprofit databases, or academic collaborations. For example, the Clinical Trials Registry – India (CTRI) offers cross-reference capabilities with Indian patient registry initiatives to support orphan drug research in the region.

Conclusion: Future of Registries in Rare Disease Trials

As clinical research becomes increasingly patient-centric and data-driven, registries will continue to play a pivotal role in accelerating rare disease drug development. Advances in genomics, real-world data, mobile health, and AI-powered analytics will further strengthen the utility of registries.

For sponsors, early investment in registry infrastructure, combined with transparent governance and patient engagement strategies, can significantly improve recruitment outcomes, regulatory alignment, and trial success.